Rivastigmine-ET

2024: Drug registration

In March 2024, Endopharm registered Rivastigmine-ET in the form of a transdermal patch. It is intended to treat dementia.

According to the press service of Endopharma, the transdermal dosage form, compared to oral use, reduces the frequency of use of the drug, the risk of adverse reactions and misuse.

source = Endopharm

Endopharm clarifies that the transdermal therapeutic systems (TTS) of the drug molecule passes through the surface of the skin into the stratum corneum, then into the epidermis and dermis, where a network of blood vessels is located, which carry the molecules to the place of exposure (brain). The creation of a transdermal therapeutic system is based on the so-called matrix systems and an adhesive that performs various functions: sticking, storing, releasing the drug and controlling the level of release of the drug. TTS ensures a constant concentration of the drug in the blood, as a result of which the loss of the drug associated with metabolism, inactivation and reduction of the drug activity as a result of the first passage through the liver, as well as the associated adverse reactions, are reduced, thereby improving the tolerance of the drug and maintaining adherence to the treatment.

According to the developers, Rivastigmine-ET blocks acetylcholine-splitting enzymes, which allows you to slow down the destruction of acetylcholine in the brain and has a positive effect on cognitive decline associated with acetylcholine deficiency in dementia associated with Alzheimer's disease. This disease is a medical and social problem due to the general trend towards an increase in life expectancy and the share of elderly people in society and accounts for more than half of the cases in the etiological structure of dementia, the company added.^[1]

Notes